Linden Thomas Advisory Services LLC Has $1.12 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Linden Thomas Advisory Services LLC grew its position in shares of ResMed Inc. (NYSE:RMD) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,490 shares of the medical equipment provider’s stock after acquiring an additional 105 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in ResMed were worth $1,116,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Morgan Stanley increased its position in shares of ResMed by 102.4% in the third quarter. Morgan Stanley now owns 2,329,618 shares of the medical equipment provider’s stock valued at $344,481,000 after acquiring an additional 1,178,547 shares during the last quarter. LGT Capital Partners LTD. bought a new stake in shares of ResMed during the 4th quarter worth approximately $117,621,000. abrdn plc lifted its stake in ResMed by 79.2% in the third quarter. abrdn plc now owns 901,485 shares of the medical equipment provider’s stock valued at $133,303,000 after acquiring an additional 398,302 shares during the last quarter. Hsbc Holdings PLC lifted its stake in ResMed by 109.9% in the third quarter. Hsbc Holdings PLC now owns 490,214 shares of the medical equipment provider’s stock valued at $72,785,000 after acquiring an additional 256,624 shares during the last quarter. Finally, UBS Group AG grew its position in shares of ResMed by 109.3% in the 3rd quarter. UBS Group AG now owns 457,717 shares of the medical equipment provider’s stock valued at $67,683,000 after acquiring an additional 239,001 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Down 0.3 %

RMD opened at $183.74 on Thursday. The stock has a fifty day moving average of $186.30 and a 200-day moving average of $171.39. The company has a market capitalization of $27.03 billion, a P/E ratio of 30.37, a P/E/G ratio of 2.26 and a beta of 0.67. ResMed Inc. has a fifty-two week low of $132.24 and a fifty-two week high of $243.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11.

ResMed (NYSE:RMD) last released its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.15 billion. ResMed had a net margin of 19.77% and a return on equity of 23.86%. ResMed’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period last year, the firm earned $1.66 earnings per share. On average, equities analysts expect that ResMed Inc. will post 7.47 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RMD. Royal Bank of Canada upped their target price on shares of ResMed from $181.00 to $182.00 and gave the company a “sector perform” rating in a report on Thursday, January 25th. Oppenheimer raised their price objective on ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Mizuho reiterated a “buy” rating and set a $215.00 target price on shares of ResMed in a research note on Wednesday, March 27th. KeyCorp assumed coverage on ResMed in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $227.00 price target on the stock. Finally, Needham & Company LLC raised their price target on ResMed from $215.00 to $224.00 and gave the company a “buy” rating in a report on Monday, April 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.20.

Insiders Place Their Bets

In other news, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $173.25, for a total value of $34,650.00. Following the completion of the sale, the general counsel now directly owns 6,688 shares in the company, valued at $1,158,696. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other ResMed news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares in the company, valued at $28,751,414.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Michael J. Rider sold 200 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the completion of the sale, the general counsel now directly owns 6,688 shares in the company, valued at $1,158,696. The disclosure for this sale can be found here. Insiders have sold a total of 11,216 shares of company stock worth $2,046,617 in the last quarter. Corporate insiders own 1.21% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.